Heidelberg Pharma announces financial figures for fiscal year 2020 and provides business update
- Application to initiate clinical trial of HDP-101 green-lighted by the FDA in February 2021
- Two more development candidates added to the pipeline
- Capital increase implemented and shareholder loans granted
- Financial figures in line with planning, with increased income and higher spending on R&D
- New financing commitment for up to EUR 30 million obtained from main shareholder dievini
- Conference call to be held on 25 March 2021 at 3:00 p.m. CET
Heidelberg Pharma AG today published its financial results and annual report for fiscal year 2020 (01 December 2019 – 30 November 2020) and its outlook for 2021.